AMGEVITA (ADALIMUMAB) Logo (EUIPO, 10/02/2017)
EUIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The Union trademark AMGEVITA (ADALIMUMAB) was filed as Figurative mark on 10/02/2017 at the European Union Intellectual Property Office.
It was registered as a trademark on 02/15/2018.
The current status of the mark is "Trademark registered".
Logodesign (Wiener Klassifikation)
#Other parts of the human body, DNA band, cells, brains, sperms, hair roots (also 2.9.12) #Punctuation marks, brackets, quotation marks #Backgrounds, in words or numerals, divided into two, horizontally #Blue #Grey
| Trademark form | Figurative mark |
| File reference | 017278086 |
| Application date | October 2, 2017 |
| Publication date | November 8, 2017 |
| Entry date | February 15, 2018 |
| Expiration date | October 2, 2027 |
Trademark owner
One Amgen Center Drive
91320-1799 Thousand Oaks,
US
91320-1799 Thousand Oaks,
US
Trademark representatives
2Amsterdam Eduard van Beinumstraat 10 3rd Floor
1077 CZ Amsterdam
NL
goods and services
5
Pharmaceutical preparations; pharmaceutical preparations and substances used for the treatment of bone, joint, intestine, colon, skin, lung, eye, bladder, blood cells, and blood vessel diseases and disorders; pharmaceutical preparations and substances for the treatment of autoimmune and immune system, inflammatory, inflammatory bowel, gastrointestinal, musculoskeletal dermatological, pulmonary, respiratory, oncological, and ophthalmic diseases and disorders; pharmaceutical preparations and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, acute disc prolapse, inflammatory bowel disease, crohn's disease, ulcerative colitis, intestinal behçet's disease, chronic pouchitis; pharmaceutical preparations and substances used for the treatment of small bowel lesions, hermansky-pudlak syndrome, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, hidradenitis suppurativa, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, uveitis, choroidal neovascularization, pyoderma gangrenosum, giant cell arteritis, netherton syndrome, anaplastic thyroid cancers,asthma, and refractory asthma
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| November 6, 2023 | Change Representative, Published |
ID: 11017278086